BioCentury
ARTICLE | Clinical News

Tedopi: Ph III Atalante 1 ongoing

January 27, 2017 4:36 AM UTC

An IDMC recommended continuation of the open-label, international Phase III Atalante 1 trial comparing subcutaneous Tedopi vs. IV docetaxel or IV pemetrexed in about 500 HLA-A2 positive patients. Pati...